The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation ...

IMUNON (IMNN) announced that the U.S. Food and Drug Administration is aligned with the protocol for the Phase 3 pivotal trial, called OVATION ...

IMNN-001, in patients with advanced ovarian cancer. IMNN-001 is a DNA immunotherapeutic drug that consists of an interleukin (IL)-12 expressing plasmid that allows for the durable, local ...

IMUNON, Inc. has announced the initiation of a Phase 3 pivotal trial, OVATION 3, for its DNA-mediated immunotherapy candidate, IMNN-001, targeting newly diagnosed advanced ovarian cancer.

IMNN-001 is a DNA immunotherapeutic drug that consists of an interleukin (IL)-12 IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian ...

IMNN-001, an immunotherapy for advanced ovarian cancer, shows promising survival data, with a Phase 3 trial set for 2025. IMUNON, Inc. reported that its DNA-mediated immunotherapy, IMNN-001 ...

The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Receive News & Ratings for Imunon ...

"2024 was a pivotal year for IMUNON. We reported robust and unprecedented data from our Phase 2 OVATION 2 Study, demonstrating that IMNN-001 is the first immunotherapy to consistently show clinical ...

“The Phase 2 OVATION 2 study data are highly encouraging, demonstrating that IMNN-001 is the first immunotherapy to achieve a clinically effective response in ovarian cancer, including benefits ...